JESUS MIGUEL
UNDA URZAIZ
Investigador/a en el periodo 2002-2023
Instituto Valenciano de Oncologia
Valencia, EspañaPublicaciones en colaboración con investigadoras/es de Instituto Valenciano de Oncologia (11)
2023
-
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial
European urology oncology, Vol. 6, Núm. 1, pp. 58-66
2017
-
Consenso sobre el manejo del cáncer de próstata resistente a la castración avanzado en España
Archivos Espanoles de Urologia, Vol. 70, Núm. 9, pp. 777-791
2016
-
Estudio retrospectivo de diferentes opciones de tratamiento conservador con Bacilo de Calmette-Guèrin en el carcinoma urotelial vesical T1G3: terapia de mantenimiento
Actas Urologicas Espanolas, Vol. 40, Núm. 6, pp. 370-377
-
Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer
Critical Reviews in Oncology/Hematology, Vol. 100, pp. 127-136
2015
-
Sequential combination of mitomycin C plus bacillus calmette-guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: Final outcome of CUETO 93009, a randomized prospective trial
European Urology, Vol. 67, Núm. 3, pp. 508-516
2014
-
Factors that predict the development of bone metastases due to prostate cancer: Recommendations for follow-up and therapeutic options
Actas Urologicas Espanolas
-
Influencia del número real de instilaciones de Bacilo de Calmette-Guérin aplicadas en el pronóstico de los tumores vesicales no músculo-infiltrantes
Actas Urologicas Espanolas, Vol. 38, Núm. 5, pp. 280-284
2013
-
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
British Journal of Cancer, Vol. 109, Núm. 1, pp. 121-130
-
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572
2009
-
LONG-TERM FOLLOW UP OF THE EFFECTIVENESS OF STANDARD DOSE BCG (81 MG. CONNAUGHT STRAIN) COMPARING WITH A THREE FOLD REDUCE DOSE (27 MG.) IN HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER. CUETO GROUP
EUROPEAN UROLOGY SUPPLEMENTS
-
Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model
Journal of Urology, Vol. 182, Núm. 5, pp. 2195-2203